Has Michael McNulty, MD received payments from drug or device companies?

Yes. Drug and device makers reported $13,474 in general payments to Michael McNulty, MD across 869 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Michael McNulty, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Michael McNulty, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Michael McNulty, MD

Pain Medicine · New Hartford, NYNPI 1013177450

Payments from drug & device makers

$13,474in general payments, 2019–2025

Across 869 payments — averaging $15.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$3K
Boston Scientific$2K
Abbott$2K
Lilly USA, LLC$497
Pfizer$493
Teva Pharmaceuticals USA, Inc.$486
plus $4K from 41 others

What the payments were for

Food & beverage$13,445100%
Education$290%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	177	$3,493
Boston Scientific	103	$2,239
Abbott	278	$2,135
Lilly USA, LLC	28	$497
Pfizer	33	$493
Teva Pharmaceuticals USA, Inc.	29	$486
Nevro Corp.	27	$453
Medtronic(2 entities)	32	$409
Lundbeck LLC	18	$337
Biohaven Pharmaceutical Holding Company Ltd.	12	$311
Averitas Pharma Inc.	14	$309
Ipsen Biopharmaceuticals, Inc	10	$199
Merz North America, Inc.	12	$192
Biohaven Pharmaceuticals, Inc.	9	$178
Si-bone, Inc.	1	$160
Amgen(2 entities)	7	$142
Almatica Pharma LLC	6	$126
Scilex Pharmaceuticals Inc.	8	$123
Merz Pharmaceuticals, LLC	5	$105
Johnson & Johnson	5	$100
Curonix LLC	3	$76
Pacira Therapeutics, Inc.	3	$71
Avanos Medical	2	$68
IBSA Pharma Inc.	4	$66
Vertex	3	$66
Novartis	4	$64
Fidia Pharma USA Inc.	3	$61
Bioventus LLC	2	$53
Collegium Pharmaceutical, Inc.	3	$49
GRT US Holding, Inc.	2	$47
Vertos Medical, Inc.	2	$44
MDD US Operations, LLC	3	$40
Stimwave Technologies Incorporated	2	$32
Tonix Medicines, Inc.	1	$31
Azurity Pharmaceuticals, Inc.	2	$29
SPR Therapeutics, Inc	5	$26
Saluda Medical Americas, Inc.	1	$22
Axsome Therapeutics, Inc.	1	$22
Cumberland Pharmaceuticals, Inc.	1	$18
Nalu Medical, Inc.	1	$18
Metacel Pharmaceuticals LLC	1	$14
Biodelivery Sciences International, Inc.	1	$13
Avanir Pharmaceuticals, Inc.	1	$13
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	1	$12
Assertio Therapeutics, Inc.	1	$12
Flowonix Medical Incorporated	1	$11
Arbor Pharmaceuticals, Inc.	1	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,474 in reported general payments places this provider in the 85th percentile of 503 pain medicine providers in New York.

See all pain medicine providers in New York →

Medicare billing

Part B allowed, 2024

$194,043

Medicare patients

172

Services billed

6,953

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Gabapentin	502	$5,575
Diclofenac Epolamine	12	$3,596
Lidocaine	21	$2,573
Pregabalin	65	$1,845
Baclofen	149	$1,628
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	92	$1,051
Diclofenac Sodium	12	$938
Cyclobenzaprine Hcl	110	$842
Tramadol Hcl	88	$421
Celecoxib	17	$334
Meloxicam	89	$318
Tizanidine Hcl	54	$317
Amitriptyline Hcl	23	$214
Naproxen	29	$191
Ibuprofen	11	$174

Paid to pharmacies, not to this prescriber.

Other pain medicine in New Hartford

Gary SchwartzBrooklyn$756K
Amitabh GulatiNew York$627K
William CaldwellStony Brook$550K
Brian DurkinPort Jefferson$459K
Grace FordeNew Hyde Park$398K
David SpinnerNew York$391K
John MarkmanRochester$300K
Naum ShaparinBronx$178K
Ashraf HenryAmherst$168K
Kenneth ChapmanStaten Island$160K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →